ARS Pharmaceuticals, Inc. SPRY Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s other income (expense)?
- ARS Pharmaceuticals, Inc. (SPRY) reported other income (expense) of -$473K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s other income (expense) changed year-over-year?
- ARS Pharmaceuticals, Inc.'s other income (expense) decreased by 114.6% year-over-year, from $3.24M to -$473K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s other income (expense) has grown at a 78.8% compound annual growth rate (CAGR), from -$789K to $8.07M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.